Logo

PHIO

Phio Pharmaceuticals Corp.

PHIO

Phio Pharmaceuticals Corp. • NASDAQ
$1.27 ▲ 3.25% (+0.04)
Market Cap $13.67 M
52w High $9.79
52w Low $0.97
Dividend Yield 0%
P/E -0.59
Volume 90.67K
Outstanding Shares 10.76M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $2.503M ▲ $-2.392M ▼ 0% $-0.44 ▲ $-2.39M ▼
Q2-2025 $0 $1.235M ▼ $-2.166M ▼ 0% $-0.45 ▲ $-2.308M ▼
Q1-2025 $0 $1.872M ▲ $-1.769M ▼ 0% $-41.07K ▼ $-1.769M ▼
Q4-2024 $0 $1.674M ▲ $-1.626M ▼ 0% $-0.37 ▲ $-1.626M ▼
Q3-2024 $0 $946K $-1.524M 0% $-1.54 $-1.59M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $10.705M ▼ $11.505M ▲ $1.666M ▲ $9.839M ▼
Q2-2025 $10.775M ▼ $11.301M ▼ $1.206M ▼ $10.095M ▼
Q1-2025 $13.278M ▲ $13.44M ▲ $1.27M ▲ $12.17M ▲
Q4-2024 $5.382M ▼ $5.738M ▼ $1.015M ▲ $4.723M ▼
Q3-2024 $5.39M $5.865M $919K $4.946M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-2.392M ▼ $-2.085M ▲ $-7K ▼ $2.022M ▲ $-70K ▲ $-2.092M ▲
Q2-2025 $-2.166M ▼ $-2.54M ▼ $-3K ▼ $40K ▼ $-2.503M ▼ $-2.543M ▼
Q1-2025 $-1.769M ▼ $-1.275M ▲ $-2K ▼ $9.173M ▲ $7.896M ▲ $-1.277M ▲
Q4-2024 $-1.626M ▼ $-1.371M ▲ $8K ▲ $1.355M ▼ $-8K ▼ $-1.372M ▲
Q3-2024 $-1.524M $-1.953M $0 $2.645M $692K $-1.953M

Five-Year Company Overview

Income Statement

Income Statement Phio is a pure R&D-stage biotech: it has essentially no product revenue over the past several years and runs a small but persistent operating loss every year. Losses appear relatively steady in size, but the reported loss per share looks volatile mainly because of repeated reverse stock splits rather than big changes in the underlying business. The core message: this is an early-stage company still firmly in the “spending to develop” phase, not in a “selling products” phase.

Balance Sheet

Balance Sheet The balance sheet is very light, with only a small pool of assets, mostly cash, and no financial debt. That’s a positive in terms of leverage, but the very small equity base and shrinking asset level suggest a thin financial cushion. Repeated reverse stock splits over the years point to long‑term pressure on the equity value and likely past dilution. Overall, the company appears financially fragile and heavily dependent on future access to capital rather than on internal resources or assets.

Cash Flow

Cash Flow Cash flow is consistently negative from operations, reflecting ongoing research and corporate overhead with no offsetting revenue. There is essentially no spending on physical assets, so the cash burn is almost entirely tied to running the business and clinical programs. Free cash flow is therefore negative and relatively steady. With a modest cash balance and recurring outflows, the company’s financial trajectory depends on its ability to periodically bring in new funding, whether via equity, grants, or partnerships.

Competitive Edge

Competitive Edge Phio occupies a narrow niche within immuno-oncology, built around its proprietary INTASYL self-delivering RNAi approach. The technology is differentiated in how it gets RNAi into cells without extra delivery vehicles, which, if validated in later trials, could be a meaningful edge. The company also benefits from patents and a focused leadership team. However, it is very small, has no approved products, and operates in a field crowded with much larger, better-funded competitors developing checkpoint inhibitors, RNA-based drugs, and cell therapies. Its competitive standing will largely hinge on whether it can produce convincing clinical results and attract partners before larger rivals close any technological gap.

Innovation and R&D

Innovation and R&D Innovation is the clear strength: INTASYL is a distinctive platform aimed at silencing genes inside immune cells to boost anti-tumor activity. The lead program, PH-762, targets PD-1 directly in the tumor environment and has shown early, encouraging responses in a small Phase 1b trial for certain skin cancers. Beyond PH-762, the same platform can, in principle, be extended to other immune targets like TIGIT and PD-L1, and possibly used in combination with cell therapies. This creates a pipeline “engine” rather than a single-product story. The flip side is classic biotech risk: all value is tied to R&D success, regulatory approvals, and consistent funding, with high uncertainty around timelines and ultimate clinical outcomes.

Summary

Phio is a tiny, high-risk, early-stage biotech driven by a potentially innovative RNAi delivery platform but with minimal financial cushion. The business model today is entirely R&D-focused: no revenue, recurring operating losses, and negative cash flow. The balance sheet is lean, debt-free but fragile, and past reverse splits highlight historical pressure on the share price and reliance on new equity. Strategically, the company’s future rests on translating its INTASYL technology and lead asset PH-762 into solid clinical data and external validation, such as partnerships. For observers, the story is mainly about scientific and clinical progress versus funding and execution risk, rather than about current financial performance.

NEWS

November 25, 2025 · 11:30 AM UTC

Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762

Read more

November 17, 2025 · 8:45 AM UTC

Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress

Read more

November 13, 2025 · 4:15 PM UTC

Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Read more

November 7, 2025 · 10:30 AM UTC

Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762

Read more

November 7, 2025 · 7:45 AM UTC

Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program

Read more